BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10625111)

  • 1. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.
    Buur-Rasmussen B; Brøsen K
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):453-9. PubMed ID: 10625111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
    Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
    Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
    J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP-mediated clozapine interactions: how predictable are they?
    Chetty M; Murray M
    Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will routine therapeutic drug monitoring have a place in clozapine therapy?
    Freeman DJ; Oyewumi LK
    Clin Pharmacokinet; 1997 Feb; 32(2):93-100. PubMed ID: 9068925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ
    Pharmacogenetics; 2003 Mar; 13(3):169-72. PubMed ID: 12618594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
    Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
    Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
    González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
    Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
    Hermida J; Paz E; Tutor JC
    Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unanticipated plasma concentrations in two clozapine-treated patients.
    Alfaro CL; McClure RK; Vertrees JE; Benavides R
    Ann Pharmacother; 2001 Sep; 35(9):1028-31. PubMed ID: 11573850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.
    Guitton C; Kinowski JM; Abbar M; Chabrand P; Bressolle F
    J Clin Pharmacol; 1999 Jul; 39(7):721-8. PubMed ID: 10392327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
    Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
    Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
    Couchman L; Morgan PE; Spencer EP; Flanagan RJ
    Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of post-mortem changes on peripheral and central whole blood and tissue clozapine and norclozapine concentrations in the domestic pig (Sus scrofa).
    Flanagan RJ; Amin A; Seinen W
    Forensic Sci Int; 2003 Mar; 132(1):9-17. PubMed ID: 12689746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS/MS method.
    Patteet L; Maudens KE; Vermeulen Z; Dockx G; De Doncker M; Morrens M; Sabbe B; Neels H
    Clin Biochem; 2014 Dec; 47(18):336-9. PubMed ID: 25289972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.
    Augustin M; Schoretsanitis G; Pfeifer P; Gründer G; Liebe C; Paulzen M
    Schizophr Res; 2019 Aug; 210():143-148. PubMed ID: 31182321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
    Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR
    Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.